Overview

Diazepam Trial in GAD65 Associated Epilepsy

Status:
Enrolling by invitation
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether diazepam reduces the frequency of seizures in GAD65 antibody associated epilepsy.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Mayo Clinic
Treatments:
Diazepam